185 related articles for article (PubMed ID: 25129332)
1. Antibacterial activities of nemonoxacin against clinical isolates of Staphylococcus aureus: an in vitro comparison with three fluoroquinolones.
Li Z; Liu Y; Wang R; Li A
World J Microbiol Biotechnol; 2014 Nov; 30(11):2927-32. PubMed ID: 25129332
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
[TBL] [Abstract][Full Text] [Related]
3. Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones.
Dalhoff A; Schubert S
Int J Antimicrob Agents; 2010 Sep; 36(3):216-21. PubMed ID: 20630710
[TBL] [Abstract][Full Text] [Related]
4. Nemonoxacin has potent activity against gram-positive, but not gram-negative clinical isolates.
Li ZX; Liu YN; Wang R; Li AM
Clin Ter; 2015; 166(6):e374-80. PubMed ID: 26794819
[TBL] [Abstract][Full Text] [Related]
5. Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis.
Marangon FB; Miller D; Muallem MS; Romano AC; Alfonso EC
Am J Ophthalmol; 2004 Mar; 137(3):453-8. PubMed ID: 15013867
[TBL] [Abstract][Full Text] [Related]
6. [Mutant prevention concentrations of fluoroquinolones for Staphylococcus aureus].
Cui JC; Liu YN; Wang R; Liang BB; Pei F; Zheng ZJ
Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1863-6. PubMed ID: 15631794
[TBL] [Abstract][Full Text] [Related]
7. Levonadifloxacin (WCK 771) exerts potent intracellular activity against
Dubois J; Dubois M
J Med Microbiol; 2019 Dec; 68(12):1716-1722. PubMed ID: 31689174
[No Abstract] [Full Text] [Related]
8. Selected Mutations by Nemonoxacin and Fluoroquinolone Exposure Among Relevant Gram-Positive Bacterial Strains in Taiwan.
Yang JJ; Cheng A; Tai HM; Chang LW; Hsu MC; Sheng WH
Microb Drug Resist; 2020 Feb; 26(2):110-117. PubMed ID: 31478786
[TBL] [Abstract][Full Text] [Related]
9. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus.
Metzler K; Hansen GM; Hedlin P; Harding E; Drlica K; Blondeau JM
Int J Antimicrob Agents; 2004 Aug; 24(2):161-7. PubMed ID: 15288315
[TBL] [Abstract][Full Text] [Related]
10. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model.
Allen GP; Kaatz GW; Rybak MJ
Int J Antimicrob Agents; 2004 Aug; 24(2):150-60. PubMed ID: 15288314
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.
Yang JC; Lee PI; Hsueh PR
Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1369-75. PubMed ID: 20658256
[TBL] [Abstract][Full Text] [Related]
12. Nemonoxacin Enhances Antibacterial Activity and Anti-Resistance Mutation Ability of Vancomycin against Methicillin-Resistant Staphylococcus aureus in an
Huang J; Guo S; Li X; Yuan F; Li Y; Xu B; Gu J; Qiao Y
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0180021. PubMed ID: 34902266
[TBL] [Abstract][Full Text] [Related]
13. Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2.
Morrow BJ; Abbanat D; Baum EZ; Crespo-Carbone SM; Davies TA; He W; Shang W; Queenan AM; Lynch AS
Antimicrob Agents Chemother; 2011 Dec; 55(12):5512-21. PubMed ID: 21911562
[TBL] [Abstract][Full Text] [Related]
14. Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.
Zhao X; Eisner W; Perl-Rosenthal N; Kreiswirth B; Drlica K
Antimicrob Agents Chemother; 2003 Mar; 47(3):1023-7. PubMed ID: 12604537
[TBL] [Abstract][Full Text] [Related]
15. In vitro antimicrobial activity of ozenoxacin against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus and Streptococcus pyogenes isolated from clinical cutaneous specimens in Japan.
Kanayama S; Ikeda F; Okamoto K; Nakajima A; Matsumoto T; Ishii R; Amano A; Matsuzaki K; Matsumoto S
J Infect Chemother; 2016 Oct; 22(10):720-3. PubMed ID: 27091753
[TBL] [Abstract][Full Text] [Related]
16. Association of norB overexpression and fluoroquinolone resistance in clinical isolates of Staphylococcus aureus from Korea.
Kwak YG; Truong-Bolduc QC; Bin Kim H; Song KH; Kim ES; Hooper DC
J Antimicrob Chemother; 2013 Dec; 68(12):2766-72. PubMed ID: 23928023
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
Lauderdale TL; Shiau YR; Lai JF; Chen HC; King CH
Antimicrob Agents Chemother; 2010 Mar; 54(3):1338-42. PubMed ID: 20065058
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic Resistance in the Treatment of Staphylococcus aureus Keratitis: a 20-Year Review.
Chang VS; Dhaliwal DK; Raju L; Kowalski RP
Cornea; 2015 Jun; 34(6):698-703. PubMed ID: 25811722
[TBL] [Abstract][Full Text] [Related]
19. Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains.
Hesje CK; Borsos SD; Blondeau JM
J Ocul Pharmacol Ther; 2009 Aug; 25(4):329-34. PubMed ID: 19650708
[TBL] [Abstract][Full Text] [Related]
20. [Resistance profiles to fluoroquinolones in clinical isolates of Gram positive cocci].
Hidalgo M; Reyes J; Cárdenas AM; Díaz L; Rincón S; Vanegas N; Díaz PL; Castañeda E; Arias CA
Biomedica; 2008 Jun; 28(2):284-94. PubMed ID: 18719726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]